Manipulating the interface between synthetic material and the human body has presented risks to patients and challenges to clinicians and medical device manufacturers for decades. Deficiencies in this interface result in sub-optimal surgical procedures, leading to possible revision surgeries and increased morbidity.

Orthobond’s technology is based on Princeton University Professor Jeffrey Schwartz’s pioneering research in the field of inorganic surface chemistry, who developed a fundamentally superior process for creating stable and optimal synthetic-to-biologic interfaces between medical devices and the human body.

The technology is a nanoscale self-assembled monolayer of phosphonate ("SAMP"). The Company has shown the ability to make biologically inert surfaces osteoconductive, anti-infective, and bioresistant, as well as covalently attach biologics and drug molecules to virtually any substrate.

One of the key attributes of SAMP technology is the covalent attachment that it creates between the surface of the substrate and a biologic. SAMP can chemically integrate virtually any molecule to the surface of virtually any material. To learn more about Orthobond's technology, make a selection from the menu on the left.